170 related articles for article (PubMed ID: 37408806)
1. Synchronous Double Primary Combined Hepatocellular-cholangiocarcinoma and Cholangiolocarcinoma in a Cirrhotic Liver.
Sakata M; Kitada K; Omote R; Sonobe H; Utsumi M; Tokunaga N; Fushimi T; Nagao R; Sakata T; Kaneyoshi T; Toyokawa T; Inagaki M
J Clin Transl Hepatol; 2023 Aug; 11(4):991-997. PubMed ID: 37408806
[TBL] [Abstract][Full Text] [Related]
2. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling.
Rosenberg N; Van Haele M; Lanton T; Brashi N; Bromberg Z; Adler H; Giladi H; Peled A; Goldenberg DS; Axelrod JH; Simerzin A; Chai C; Paldor M; Markezana A; Yaish D; Shemulian Z; Gross D; Barnoy S; Gefen M; Amran O; Claerhout S; Fernández-Vaquero M; García-Beccaria M; Heide D; Shoshkes-Carmel M; Schmidt Arras D; Elgavish S; Nevo Y; Benyamini H; Tirnitz-Parker JEE; Sanchez A; Herrera B; Safadi R; Kaestner KH; Rose-John S; Roskams T; Heikenwalder M; Galun E
J Hepatol; 2022 Dec; 77(6):1631-1641. PubMed ID: 35988690
[TBL] [Abstract][Full Text] [Related]
3. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
4. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
[TBL] [Abstract][Full Text] [Related]
5. An international multicentre evaluation of treatment strategies for combined hepatocellular-cholangiocarcinoma
Claasen MPAW; Ivanics T; Beumer BR; de Wilde RF; Polak WG; Sapisochin G; IJzermans JNM
JHEP Rep; 2023 Jun; 5(6):100745. PubMed ID: 37234277
[TBL] [Abstract][Full Text] [Related]
6. Post-resection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma cannot be predicted by the 2019 World Health Organization classification.
Kim M; Hwang S; Ahn CS; Kim KH; Moon DB; Song GW; Jung DH; Hong SM
Asian J Surg; 2021 Nov; 44(11):1389-1395. PubMed ID: 33766528
[TBL] [Abstract][Full Text] [Related]
7. Combined hepatocellular-cholangiocarcinoma: An update.
Beaufrère A; Calderaro J; Paradis V
J Hepatol; 2021 May; 74(5):1212-1224. PubMed ID: 33545267
[TBL] [Abstract][Full Text] [Related]
8. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma.
Murugesan K; Sharaf R; Montesion M; Moore JA; Pao J; Pavlick DC; Frampton GM; Upadhyay VA; Alexander BM; Miller VA; Javle MM; Bekaii Saab TS; Albacker LA; Ross JS; Ali SM
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34476330
[TBL] [Abstract][Full Text] [Related]
9. Combined Hepatocellular-Cholangiocarcinoma: Changes in the 2019 World Health Organization Histological Classification System and Potential Impact on Imaging-Based Diagnosis.
Kim TH; Kim H; Joo I; Lee JM
Korean J Radiol; 2020 Oct; 21(10):1115-1125. PubMed ID: 32729276
[TBL] [Abstract][Full Text] [Related]
10. Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice.
Liu Y; Xin B; Yamamoto M; Goto M; Ooshio T; Kamikokura Y; Tanaka H; Meng L; Okada Y; Mizukami Y; Nishikawa Y
Cancer Sci; 2021 Aug; 112(8):3111-3124. PubMed ID: 34051011
[TBL] [Abstract][Full Text] [Related]
11. Combined hepatocellular-cholangiocarcinoma and its mimickers: Diagnostic pitfalls in surgical pathology.
Laohawetwanit T; Lerttanatum N; Wanpiyarat N; Manasilp N; Chaiparnich S
Ann Diagn Pathol; 2021 Aug; 53():151770. PubMed ID: 34147845
[TBL] [Abstract][Full Text] [Related]
12. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
Calderaro J; Di Tommaso L; Maillé P; Beaufrère A; Nguyen CT; Heij L; Gnemmi V; Graham RP; Charlotte F; Chartier S; Wendum D; Vij M; Allende D; Diaz A; Fuster C; Rivière B; Herrero A; Augustin J; Evert K; Calvisi DF; Leow WQ; Leung HHW; Bednarsch J; Boleslawski E; Rela M; Chan AW; Forner A; Reig M; Pujals A; Favre L; Allaire M; Scatton O; Uguen A; Trépo E; Sanchez LO; Chatelain D; Remmelink M; Boulagnon-Rombi C; Bazille C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Kather JN; Gouw ASH; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Nault JC; Laurent A; Amaddeo G; Regnault H; de Martin E; Sempoux C; Navale P; Shinde J; Bacchuwar K; Westerhoff M; Lo RC; Sebbagh M; Guettier C; Lequoy M; Komuta M; Ziol M; Paradis V; Shen J; Caruso S
J Hepatol; 2022 Dec; 77(6):1586-1597. PubMed ID: 35987274
[TBL] [Abstract][Full Text] [Related]
13. Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma.
Sciarra A; Park YN; Sempoux C
Hum Pathol; 2020 Feb; 96():48-55. PubMed ID: 31931021
[TBL] [Abstract][Full Text] [Related]
14. Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma.
Granata V; Fusco R; Venanzio Setola S; Sandomenico F; Luisa Barretta M; Belli A; Palaia R; Tatangelo F; Grassi R; Izzo F; Petrillo A
Radiol Oncol; 2020 May; 54(2):149-158. PubMed ID: 32463393
[TBL] [Abstract][Full Text] [Related]
15. Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update.
Roßner F; Sinn BV; Horst D
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672443
[TBL] [Abstract][Full Text] [Related]
16. Combined Hepatocellular-Cholangiocarcinoma: An Update on Pathology and Diagnostic Approach.
Choi JH; Ro JY
Biomedicines; 2022 Jul; 10(8):. PubMed ID: 36009374
[TBL] [Abstract][Full Text] [Related]
17. Update on the Diagnosis and Treatment of Combined Hepatocellular Cholangiocarcinoma.
Chu KJ; Kawaguchi Y; Wang H; Jiang XQ; Hasegawa K
J Clin Transl Hepatol; 2024 Feb; 12(2):210-217. PubMed ID: 38343605
[TBL] [Abstract][Full Text] [Related]
18. [Cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in cirrhotic patients].
Salinas M; Simian D; Carreño L; Cattaneo M; Urzúa Á; Sauré A; Lembach H; Castillo J; Díaz JC; Poniachik J
Rev Med Chil; 2022 Nov; 150(11):1431-1437. PubMed ID: 37358168
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma.
Ishii T; Ito T; Sumiyoshi S; Ogiso S; Fukumitsu K; Seo S; Taura K; Uemoto S
World J Surg Oncol; 2020 Dec; 18(1):319. PubMed ID: 33276780
[TBL] [Abstract][Full Text] [Related]
20. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
